Table 2.

HCV testing and new positive tests by calendar year among GBM prescribed PrEP in Australia (2016–2022)

	Year	Consultation	Tested	% tested (95% CI)	Positive test	% positive (95% CI)
HCV antibody*	2016	6780	5381	79.4 (78.4 to 80.3)	37	0.7 (0.5 to 0.9)
	2017	10 061	7957	79.1 (78.3 to 79.9)	33	0.4 (0.3 to 0.6)
	2018	13 446	9479	70.5 (69.7 to 71.3)	27	0.3 (0.2 to 0.4)
	2019	13 987	9705	69.4 (68.6 to 70.1)	28	0.3 (0.2 to 0.4)
	2020	13 422	8818	65.7 (64.9 to 66.5)	21	0.2 (0.1 to 0.4)
	2021	13 022	8772	67.4 (66.5 to 68.2)	12	0.1 (0.1 to 0.2)
	2022	14 294	9311	65.1 (64.4 to 65.9)	20	0.2 (0.1 to 0.3)
Naïve HCV RNA†	2016	55	34	61.8 (47.7 to 74.6)	15	44.1 (27.2 to 62.1)
	2017	67	42	62.7 (50.0 to 74.2)	19	45.2 (29.8 to 61.3)
	2018	68	39	57.4 (44.8 to 69.3)	10	25.6 (13.0 to 42.1)
	2019	66	40	60.6 (47.8 to 72.4)	11	27.5 (14.6 to 43.9)
	2020	72	38	52.8 (40.7 to 64.7)	9	23.7 (11.4 to 40.2)
	2021	61	29	47.5 (34.6 to 60.7)	4	13.8 (3.9 to 31.7)
	2022	62	26	41.9 (29.5 to 55.2)	2	7.7 (0.9 to 25.1)
Follow-up HCV RNA‡	2016	10	5	50.0 (18.7 to 81.3)	1	20.0 (0.5 to 71.6)
	2017	24	16	66.7 (44.7 to 84.4)	0	0.0 (0.0 to 20.6)
	2018	33	22	66.7 (48.2 to 82.0)	1	4.5 (0.1 to 22.8)
	2019	42	26	61.9 (45.6 to 76.4)	3	11.5 (2.4 to 30.2)
	2020	46	19	41.3 (27.0 to 56.8)	1	5.3 (0.1 to 26.0)
	2021	44	30	68.2 (52.4 to 81.4)	0	0.0 (0.0 to 11.6)
	2022	36	23	63.9 (46.2 to 79.2)	1	4.3 (0.1 to 21.9)

*Among GBM with no previous positive HCV antibody or RNA test recorded in ACCESS (n=33 848).

†Among GBM with an antibody positive test but no previous positive HCV RNA test recorded in ACCESS (n=255).

‡Among GBM with a previous positive HCV RNA and at least one subsequent negative HCV RNA test recorded in ACCESS (n=93).

ACCESS, Australian Collaboration for Coordinated Enhanced Sentinel Surveillance; GBM, gay and bisexual men; HCV, hepatitis C virus; PrEP, pre-exposure prophylaxis.